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ABSTRACT 
Objective: The objective of this selective EBM review is to determine whether or not 
secukinumab improves self-reported quality of life in patients with moderate-to-severe 
ankylosing spondylitis when taken regularly. 
Study design: A systematic review of three randomized placebo-controlled trials (RCTs), 
published in peer-reviewed journals between 2013 and 2015, all in the English language. 
Data sources: All three studies were found and accessed on PubMed. 
Outcomes measured: Patient quality of life was assessed in all three studies using the 
Ankylosing Spondylitis Quality of Life (ASQoL) questionnaire and reported as mean change 
from baseline. ASQoL is scored from 0-18 with a higher score representing a lower quality of 
life and a greater degree of disability.  
Results: With the exception of the smallest dose tested in the initial study conducted by Baeten 
et al. (2013), all other tested doses of secukinumab were shown to improve self-reported quality 
of life in patients with moderate-to-severe disease compared to placebo. 
Conclusions: The results of these studies indicate that given a sufficient dose, regular 
administration of secukinumab can lead to improvements in self-reported quality of life. This is 
especially important given that patients selected for some of these studies already had inadequate 
responses to max doses of NSAIDs and/or TNF-α inhibitors, which have been the only available 
therapies. 
Keywords: ankylosing spondylitis, secukinumab 
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INTRODUCTION 
 
Ankylosing spondylitis (AS) is a chronic inflammatory condition affecting the joints of 
the axial skeleton, which results in pain, new bone formation, and progressive stiffening. AS is in 
a group of conditions known as seronegative spondyloarthropathies, which is indicative of the 
fact that they are not currently associated with any specific serum antibodies. Unlike many other 
causes of back pain, AS is most often seen in patients in their late teens and early 20s. Males are 
more frequently affected than females, and symptoms are typically more severe in males as well. 
Pain associated with AS is often worse in the morning and stiffness can last for hours; however, 
these symptoms improve with activity in contrast to degenerative or acute causes of back pain, 
which are more commonly exacerbated by movement. The disease usually first affects the 
sacroiliac (SI) joints, and with progression of the disease, increasingly cephalad portions of the 
spine are affected eventually resulting in complete spinal fusion.1 As one might expect, this leads 
to significant discomfort, loss of mobility, and reduction in quality of life (QoL). While axial 
disease is the hallmark of AS, patients may also experience changes and acute flares to 
peripheral joints. Other signs and symptoms of AS include fatigue, SI joint tenderness, sleep 
disturbance, enthesopathy, and in late disease, loss of lumbar lordosis, kyphosis, and dyspnea.2   
With an incidence of only 0.2 – 0.5% of the general population of the United States, AS 
is not a particularly common disease.3 Incidence is highest at 6.5% in HLA-B27 positive 
patients, but this gene is only present in 6.1% of the US population.4,5 That being said, back pain, 
a primary symptom of AS, is incredibly common. Researchers in 2013 reviewed the medical 
records of 142, 377 individuals in one Minnesota county across 5 years and found that back pain 
was the third most common complaint amongst all age groups.6 So, while AS may be 
uncommon, it is important to recognize as a potential cause of back pain, especially if presenting 
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in a younger patient. Additionally, physician assistants frequently work in primary care, which is 
often where complaints of back pain are first addressed. If PAs and other providers are able to 
better recognize and differentiate AS from other causes of back pain, then appropriate 
management can begin leading to better quality of life for patients.  
As with many diseases, patients with AS are burdened by significant medical costs. One 
study calculated the average yearly all-cause cost associated with AS at $17,728 per year.7 On 
top of that, many patients with AS take time off of work, and as a result, suffer from lost wages. 
While some of the time taken off work is undoubtedly due to severity of symptoms and inability 
to attend work, these patients also spend a significant amount of time obtaining care. On average, 
a patient with AS has 10.8 office visits, 6.6 hospitalizations, and 2 ER visits per year.7 In 
comparison, the Centers for Disease Control & Prevention (CDC) reported that in 2015 the 
average person within the United States utilized approximately 3.1 office visits, 0.41 
hospitalizations, and 0.43 ER visits that year.8,9  
 The primary pathologic processes in the development of ankylosing spondylitis are 
inflammation, cartilage erosion, and importantly, ossification. Early in disease, MRI may detect 
bilateral and symmetric sacroiliitis. With more time, inflammation and sclerosis at the edges of 
the annulus fibrosus result in a characteristic “shiny corner” sign, which progresses to 
ossification and formation of bridging syndesmophytes. While this occurs, anterior and lateral 
ligaments of the spine become calcified. The result is spinal fusion and the appearance of a 
“bamboo spine” on plain radiographs.1 Two factors that have been limiting research into more 
precise pathophysiology are the slow progression of the disease and the technically difficult task 
of obtaining samples of affected tisue.4  
            As noted above, there is a well-recognized link between HLA-B27 (B27) and AS. The 
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presence of B27 not only increases the risk of disease but is also associated with increased 
severity, and while 90% of individuals with AS are B27-positive, it is not a requirement for 
disease. As part of the major histocompatibility complex (MHC), B27 is responsible for 
presenting proteins to T-cells for recognition of intracellular pathogens and activating natural 
killer (NK) cells. B27 exhibits preferential binding for the NK receptors, which may explain part 
of its role in pathogenesis. Recent genetic studies have identified other gene products that may 
influence the activity of B27. Inflammation is initially dominated by the presence of 
mononuclear cells and osteoclasts, which degrade trabecular bone. Accordingly, bone resorption 
markers, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) are elevated in 
patients with active AS. Other consistent findings within SI joints of affected individuals are 
high levels of T-cells, TNF-α protein, macrophages, mRNA, and other pro-inflammatory 
cytokines such as IL-10, IL-15, IL-17 and IL-23.4,10 It is currently hypothesized that 
inflammation is paradoxically prerequisite and inhibitory in the process of new bone growth, 
which may explain why syndesmophytes continue to form despite treatment with potent anti-
inflammatories like TNF-α inhibitors.4  
 Currently, no therapies have shown efficacy in slowing the progression of disease or 
inducing remission.11 Until such a discovery is made, the focus remains on minimizing 
symptoms and improving quality of life. Anti-inflammatories such as non-steroidal anti-
inflammatory drugs (NSAIDs) and corticosteroids, physical therapy, and opiate analgesics are 
commonly employed for this purpose. Physical therapy, including hydrotherapy, and daily 
stretching are important for prolonging better posture, flexibility, and mobility.11 Corticosteroids 
are somewhat controversial as they have little efficacy in axial disease and regular use leads to 
osteopenia, among other problems.1 TNF-α inhibitors have been essentially the only option for 
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patients with refractory disease. Although disease-modifying antirheumatic drugs (DMARDs) 
like methotrexate and sulfasalazine are sometimes prescribed, they have not proven to be 
effective in axial disease and are generally reserved for cases of concomitant and/or transient 
peripheral disease. Firstline treatment involves high dose NSAIDs with education about 
nonpharmacologic therapy and the use of TNF-α inhibitors, if refractory. Adjuncts include 
DMARDs and corticosteroids for peripheral arthritis. Smoking has also been linked to 
progression of axial disease, so cessation should be encouraged.11  
 Secukinumab is a fully human biologic agent that targets the cytokine IL-17A (IL-17) 
instead of the longtime target of TNF-α. This alone is potentially important because patients with 
symptoms refractory to TNF-α inhibitors have been largely without alternatives. Research has 
shown that IL-17 is normally involved in the elimination of bacterial and fungal pathogens, but 
dysregulation of this cytokine results in overactivation of the inflammatory process and 
subsequent disease. This process has been linked to rheumatoid arthritis, multiple sclerosis, 
inflammatory bowel disease, psoriasis, uveitis, and ankylosing spondylitis making IL-17 a prime 
target of therapy for reducing inflammation and improving symptoms.12  
OBJECTIVE 
The objective of this selective evidence-based medicine (EBM) review is to determine 
whether or not secukinumab improves self-reported QoL in patients with moderate-to-severe 
ankylosing spondylitis when taken regularly. 
METHODS 
 This systematic review takes into account the results of three double-blind, randomized, 
placebo-controlled trials (RCTs). Two of the studies continued past their primary endpoints and 
safety windows to a total of 5 years. All three trials were found and accessed personally via 
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PubMed using the search terms ‘ankylosing spondylitis’ and ‘secukinumab.’ The articles were 
published in peer-reviewed journals in the English language between 2013 and 2015. These 
articles were chosen because of their relevance to the objective and their inclusion of self-
reported QoL as a measured outcome. Inclusion criteria for studies in this review were: double-
blind RCTs, studies published within the last 10 years, use of secukinumab on patients with AS, 
and ASQoL as a reported measure. Exclusion criteria were: studies with published systematic 
reviews and studies not assessing POEMs.  
 In each of the three studies being reviewed, patients must have been ≥18-years-old and be 
men or non-pregnant women. In Baeten et al. (2013), patients must also have been ≤65-years-
old. In all three studies, the patients must have been diagnosed with AS as defined by the 
Modified New York Criteria, have a score of ≥4 on the Bath Ankylosing Spondylitis Disease 
Activity Index (BASDAI) indicating moderate-to-severe disease, and be experiencing spinal pain 
≥4/10cm on the visual analog pain scale.13,14 Subjects in each study were randomized into groups 
that would either receive doses of secukinumab or matched placebo. Apart from ASQoL, a 
number of other outcomes were reported in each study, but will not be discussed, including 
ASAS20, ASAS40, ASAS5/6, hsCRP, BASDAI, BASFI, SF-36, and MRI Berlin score. 
Statistics used in these studies include p-value and mean change from baseline. Additional 
details about the demographics of the reviewed studies can be found below in Table 1. 
OUTCOMES MEASURED 
 While many outcomes were reported, the sole focus of this review is on patient-reported 
QoL. This metric was assessed in each study using the Ankylosing Spondylitis Quality of Life 
(ASQoL) questionnaire. The questionnaire is comprised of 18 ‘yes’ or ‘no’ questions pertaining 
to the patient’s degree of symptoms and aspects of life that are affected by AS. Questions ask 
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Table 1: Demographics & Characteristics of included studies 
 
Study Type # 
Pts 
Age 
(yrs) 
Inclusion criteria Exclusion criteria W/D Interventions 
Baeten, 
201313   
RCT 60 42.8 
±9.9 
• 18-65 y/o with 
moderate-to-
severe AS defined 
by Modified New 
York Criteria and 
BASDAI score of 
≥4, and spinal pain 
≥4/10cm on the 
visual analog pain 
scale 
• Taking ≥ 1 
NSAID for ≥ 3 
months at max 
dose with 
inadequate 
response 
• No evidence of 
liver disease or 
injuries on LFTs 
• Patients on prior 
TNF-α blockers or 
immunosuppressants 
other than MTX, 
SSZ, and systemic 
corticosteroids must 
have a 1-month 
washout period prior 
to baseline 
• MTX, SSZ, and/or 
NSAIDs must be at a 
stable dose ≥4 weeks 
prior to baseline and 
throughout the study 
and cannot exceed 
10mg/day for 
steroids or 25mg/day 
for MTX 
• Positive HIV, HBV, 
or HCV test results 
• Any evidence of 
active systemic 
infection within the 
past 2 weeks 
including positive 
chest X-ray 
• Current S/Sx of 
other specified 
diseases 
5 Secukinumab 
10 or 1 or 0.1 
mg/kg IV given 
on days 2 and 
22 
Baeten, 
201514  
RCT 371 41.8 
±12.
4 
• ≥18 y/o with 
moderate-to-
severe AS defined 
by Modified New 
York Criteria and 
BASDAI score of 
≥4, spinal pain 
≥4/10cm on the 
visual analog pain 
scale 
• ≤ 1 TNF-α 
inhibitor or 
NSAIDs with 
inadequate 
response 
• Must be at a stable 
dose of NSAID 
• Pregnant or lactating 
females 
• Total ankylosis of 
the spine 
• CXR demonstrating 
infection or 
malignancy 
• Prior treatment with 
any biologic immune 
modulating agent 
except those that 
target TNF-α 
• Prior treatment with 
cell-depleting 
therapies 
13 Secukinumab 
10 mg/kg IV 
q2weeks x3 
followed by 
either 75mg or 
150mg SC 
q4weeks  
Baeten, 
201514  
RCT 219 43.3 
±12.
9 
11 Secukinumab 
75 mg or 150 
mg SC weekly 
for 4 weeks, 
then every 4 
weeks 
thereafter 
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about pain, stiffness, fatigue, depression, and functionality in simple ways that allow the 
questionnaire to quickly assess the patient’s perceived QoL. Each affirmative response is given a 
value of 1, and the assessment is scored on a scale of 0 to 18 with higher scores indicating a 
lower QoL. The ASQoL has previously proven to have high test-retest reliability and congruence 
with more complex assessments.15 
RESULTS 
Baeten et al. (2013) was a proof-of-concept RCT conducted in two parts that included a 
small number of subjects (n=60). The article itself only discusses the results of the first half of 
the study, which included 30 subjects, but the results of their complete study are available in the 
supplement allowing analysis of the complete study. The study was conducted over a period of 
28 weeks and subjects were randomized into 4 groups placing 30 subjects in the 10 mg/kg group, 
12 subjects in each of the 1.0 mg/kg and 0.1 mg/kg groups, and 6 subjects in the placebo group. 
The study recorded ASQoL at four separate time points, once at baseline and again at day 29, 
week 12, and week 28. The results showed that the 10 mg/kg and 1.0 mg/kg groups experienced 
clinically relevant improvements in QoL, which will be defined as a reduction in ASQoL of ≥2, 
at day 29 and week 12. This is an important result because the final dose of secukinumab was 
given on day 22, which indicates that the medication has a lasting effect, and as it wears off, 
symptoms once again worsen and QoL declines. In comparison, the 0.1 mg/kg dose and placebo 
did not produce a clinically relevant improvement in QoL at any point in the study.16 (Table 2) 
Adverse events were common and occurred in 87% of subjects on secukinumab and 100% of 
subjects on placebo. The most common complaints among secukinumab users were headache 
(20.4%), diarrhea (16.7%), and nasopharyngitis (16.7%). Serious events occurred in 3 subjects 
and included a subcutaneous abscess and anaphylactic reaction in patients on secukinumab, and 
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elevated blood pressure in a patient on placebo.17  
Table 2: Average ASQoL at baseline and mean change from baseline at different time points for 
each dose of secukinumab with (standard deviation). Clinically relevant reductions presented in 
bold. 
 10 mg/kg 1.0 mg/kg 0.1 mg/kg Placebo 
Baseline 12.1 (3.49) 14.8 (3.33) 8.3 (3.32) 10.3 (5.57) 
Day 29 -3.2 (3.78) -3.1 (2.63) -0.7 (2.26) -0.7 (2.58) 
Week 12 -2.7 (2.91) -2.7 (4.71) -1.3 (3.16) 0.0 (1.00) 
Week 28 -1.4 (3.37) -1.3 (3.66) -0.9 (2.15) -1.3 (2.06) 
 
 The Measure 1 study was much larger in scale (n=371) and assessed the efficacy of 150 
mg and 75 mg subcutaneous secukinumab after receiving IV loading doses. The study ran for 16 
weeks to its primary endpoint, at which time the placebo group was divided into two groups by 
prior response to TNF-α inhibitor treatment. Non-responders started one of the two subcutaneous 
doses of secukinumab, while responders continued placebo until week 24, at which point they 
too began secukinumab therapy. Mean change from baseline of ASQoL was reported at weeks 
16 and 52; however, no baseline ASQoL values were provided. The study ran for two years with 
a three-year extension study. At both assessments, subjects being treated with secukinumab 
experienced clinically relevant improvements in self-reported QoL, while subjects on placebo 
did not. Based on mean change from baseline in ASQoL, there was little difference in efficacy 
between the two dosing regimens. (Table 3) No p-value was noted for week 52 due to absence of 
a placebo group. During the 16-week placebo-controlled phase, 68% of patients taking 
secukinumab experienced adverse events compared to 56% on placebo. The most common 
adverse events were nasopharyngitis (12%), dyslipidemia (10%), and headache (8%). Incidence 
of infection was also higher in the secukinumab group (30%) compared to placebo (12).14,18  
Table 3: Mean change from baseline in ASQoL. Clinically relevant reductions presented in bold.  
(† = p < 0.001) 
 150 mg 75 mg Placebo 
Week 16 -3.58† -3.61† -1.04 
Week 52 -4.68 -4.49 N/A 
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 The Measure 2 study was conducted alongside Measure 1 and was of similar scale 
(n=219). The purpose of this study was to evaluate the efficacy of secukinumab 150 mg or 75 mg 
subcutaneously with weekly SC loading doses instead of IV. Measure 2 also ran for 16 weeks to 
its primary endpoint, and as with Measure 1, the placebo group was then divided into the two 
treatment arms. The treatment groups then continued to receive secukinumab at the assigned 
dose every 4 weeks up to the end of the 5-year study; however, data was only available for 
review up to week 52. Results from the study showed that both doses were capable of producing 
a significant improvement in the ASQoL compared to placebo with the 150 mg dose appearing 
to be consistently more effective. The incidence of adverse events was nearly equal in the 
treatment (61%) and placebo groups (64%); however, the incidence of infection was again higher 
in the treatment arm (32% vs. 27%). Nasopharyngitis (10%), headache (8%), and nausea (3%) 
were among the most common complaints.14,18 (Table 4) 
Table 4: Mean change from baseline in ASQoL. Clinically relevant reductions presented in bold. 
(‡ = p <0.01) 
 150 mg 75 mg Placebo 
Week 16 -4.00‡ -3.33 -1.37 
Week 52 -5.23 -4.13 N/A 
 
DISCUSSION 
  The most significant result is that every tested regimen of secukinumab, except 0.1 
mg/kg IV, was effective in improving patient QoL compared to placebo. Another important 
finding was that the incidence of infection was higher in subjects treated with secukinumab 
compared to placebo in all three RCTs. One important difference between Baeten et al. (2013) 
and Measure 1 and 2 was that in the latter two studies, the researchers sought out patients that 
had an inadequate response to TNF-α inhibitors. Comparing these two studies and secukinumab 
against phase 3 trials of TNF-α inhibitors showed similar response rates; however, because 30-
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40% of the patients in Measure 1 and Measure 2 had previously been on TNF-α inhibitors, 
secukinumab may have an indication in AS patients that have failed prior TNF-α therapy.14   
 Secukinumab was initially approved by the FDA in 2015 with the indication of moderate-
to-severe plaque psoriasis and the tradename Cosentyx®. In 2016, after the results of these 
studies had been published, the FDA added AS as an indication for use. At that same time, the 
medication was also approved for use in psoriatic arthritis. The two approved regimens for 
treating AS only vary by the presence of a 4-week loading dose period as in Measure 2. If giving 
the loading dose, patients receive 150 mg SC weekly for the first 4 weeks and one dose every 4 
weeks thereafter. If no loading dose is being given, patients only receive 150 mg SC every 4 
weeks.19  
 Secukinumab currently does not have any black box warnings, and the only absolute 
contraindication is in patients that have experienced a hypersensitivity reaction to secukinumab 
or one of its components. However, several other precautions must be taken when prescribing 
this medication. As observed in the trials, secukinumab increases the risk of infection and should 
be used with caution in patients with recurrent or chronic infections. If patients do develop a 
serious infection while being treated, secukinumab should be discontinued until resolution of the 
infection. As is standard with many immunosuppressant agents, patients should be tested for TB 
prior to initiation of treatment and treatment should not be started in active cases of TB. Due to 
the immunosuppressive mechanism, candidates for secukinumab should be updated on all 
vaccines prior to treatment. If vaccinating during treatment, non-live vaccines may not be 
effective, and live vaccines should be avoided. There is also some concern that secukinumab 
may induce or exacerbate IBD, and patients should be made aware that they may develop this 
condition or have worsening of their flares.20 
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 Except for the Baeten et al. (2013), the RCTs evaluated in this review were of good 
quality in that they were conducted over long periods of time with a large number of subjects. A 
significant limitation of this review is that patient QoL was not assessed as a primary endpoint in 
any study and was inadequately reported given the overall length of these studies. Measure 1 and 
2 were each conducted for a total of 260 weeks, but the last reported value for change in baseline 
ASQoL was at week 52. Additionally, statistics to indicate the significance of the change in 
ASQoL, such as p-value, NNT, and NNH, were either reported inconsistently or not at all.  
CONCLUSION 
 The question posed by this review has been answered in the affirmative, and 
secukinumab when taken regularly has proven to increase self-reported QoL in AS patients with 
moderate-to-severe disease. These studies assessed a number of metrics, but changes in ASQoL 
could have been better reported to give a more precise understanding of the findings. More 
frequent reporting of change from baseline in ASQoL throughout the duration of the study along 
with statistics to support the data should be a goal of future studies. An important result from 
Measure 1 and Measure 2 was that secukinumab may be effective in improving QoL in patients 
that had previously failed TNF-α therapy. A study directly comparing secukinumab and TNF-α 
inhibitors would be helpful in determining which is more effective, and a study doing so has 
recently started. Novartis Pharmaceuticals announced the SURPASS study in January of 2018, 
which is a 1-year RCT comparing two doses of secukinumab against adalimumab in AS patients. 
However, the endpoints of this study are related to radiographic evidence of spinal disease 
progression, inflammation, and syndesmophyte formation. Unfortunately, they will not be 
evaluating patient-reported QoL in this study.21 Hopefully a future study will assess this metric.
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